Clareo Health | Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This study was prematurely terminated due to administrative reasons and not due to any safety or efficacy concerns.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Sign written informed consent
Diagnosed with normal tension glaucoma
Intraocular pressure measurements in at least 1 eye as specified in the protocol
Willing and able to attend all study visits
You may not be if
History of hypersensitivity to any of the study drugs
Use of medications prohibited by the protocol
Pregnant or nursing
Of child-bearing potential unless using contraception, as specified in the protocol
Any form of glaucoma other than open angle glaucoma in either eye
Chronic, recurrent or severe inflammatory eye disease
Ocular trauma or surgery within the past 6 months in either eye; ocular infection or laser surgery within the past 3 months in either eye (all from screening)
Conditions which would make the patient, in the opinion of the Investigator, unsuitable for the study.
